Long Term Exposure to Tenofovir Disoproxil Fumarate-Containing Antiretroviral Therapy Is Associated with Renal Impairment in an African Cohort of HIV-Infected Adults

被引:7
|
作者
Agbaji, Oche O. [1 ,2 ]
Abah, Isaac O. [2 ,3 ]
Ebonyi, Augustine O. [2 ,4 ]
Gimba, Zumnan M. [1 ]
Abene, Esla E. [1 ]
Gomerep, Simji S. [1 ]
Falang, Kakjing D. [2 ,5 ]
Anejo-Okopi, Joseph [2 ,6 ]
Agaba, Patricia A. [2 ,7 ]
Ugoagwu, Placid O. [2 ]
Agaba, Emmanuel I. [1 ]
Imade, Godwin E. [2 ,8 ]
Sagay, Atiene S. [2 ,8 ]
Okonkwo, Prosper [9 ]
Idoko, John A. [1 ]
Kanki, Phyllis J. [10 ]
机构
[1] Univ Jos, Jos Univ Teaching Hosp, Dept Med, Jos, Nigeria
[2] Jos Univ Teaching Hosp, APIN supported HIV Treatment Ctr, Jos, Nigeria
[3] Jos Univ Teaching Hosp, Dept Pharm, Jos, Nigeria
[4] Univ Jos, Jos Univ Teaching Hosp, Dept Paediat, Jos, Nigeria
[5] Univ Jos, Dept Pharmacol, Jos, Nigeria
[6] Univ Jos, Dept Microbiol, Jos, Nigeria
[7] Univ Jos, Jos Univ Teaching Hosp, Dept Family Med, Jos, Nigeria
[8] Univ Jos, Jos Univ Teaching Hosp, Dept Obstet & Gynaecol, Jos, Nigeria
[9] APIN Publ Hlth Initiat Ltd Gte, Abuja, Nigeria
[10] Harvard TH Chan Sch Publ Hlth, Dept Immunol Infect Dis, Boston, MA USA
基金
美国国家卫生研究院;
关键词
HIV; ART; tenofovir; renal impairment; Nigeria;
D O I
10.1177/2325958218821963
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives and Method: There are growing concerns of tenofovir disoproxil fumarate (TDF)-associated renal toxicity. We evaluated the effect of long-term TDF exposure on renal function in a cohort of HIV-1-infected Nigerians between 2006 and 2015. Multivariate logistic regression was used to identify predictors of renal impairment at different time over 144 weeks of antiretroviral therapy (ART). Results: Data of 4897 patients, median age 42 years (interquartile range: 36-49), and 61% females were analyzed. The prevalence of renal impairment increased from 10% at week 24 to 45% at 144 weeks in TDF-exposed participants compared to an increase from 8% at 24 weeks to 14% at 144 weeks in TDF-unexposed participants. Tenofovir disoproxil fumarate exposure predicted the risk of renal impairment at 144 weeks of ART (odds ratio: 2.36; 95% confidence interval: 1.28-4.34). Conclusion: Long-term exposure to TDF-based ART significantly increases the likelihood of renal impairment. The continued use of TDF-based regimen in our setting should be reviewed. We recommend the urgent introduction of tenofovir alafenamide-based regimen in the HIV treatment guidelines of Nigeria and other resource-limited countries.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Evaluating the effects of HIV and antiretroviral treatment containing tenofovir disoproxil fumarate on bone density measured by the achilles insight ultrasound in HIV-infected patients: a retrospective study
    Eschenheimer, Ben
    ACTA CLINICA BELGICA, 2019, 74 : 58 - 58
  • [42] Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a Primary Healthcare Setting in South Africa
    Kamkuemah, Monika
    Kaplan, Richard
    Bekker, Linda-Gail
    Little, Francesca
    Myer, Landon
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2015, 20 (04) : 518 - 526
  • [43] Decreased bone density (BMD) in HIV-infected children treated with tenofovir disoproxil fumarate (TDF)-containing HAART
    Gafni, RI
    Hazra, R
    Reynolds, JC
    Maldarelli, F
    Tullio, A
    DeCarlo, E
    Worrell, C
    Zuckerman, J
    Zeichner, S
    PEDIATRIC RESEARCH, 2004, 55 (04) : 329A - 329A
  • [44] Long-term Renal Effects of Tenofovir-Disoproxil-Fumarate in Vertically HIV-Infected Children, Adolescents, and Young Adults: A 132-Month Follow-Up Study
    Giacomet, Vania
    Nannini, Pilar
    Vigano, Alessandra
    Erba, Paola
    Benincaso, Annarita
    Bedogni, Giorgio
    Cattaneo, Dario
    Falvella, Felicia Stefania
    Zuccotti, Gian Vincenzo
    CLINICAL DRUG INVESTIGATION, 2015, 35 (07) : 419 - 426
  • [45] Long-term Renal Effects of Tenofovir-Disoproxil-Fumarate in Vertically HIV-Infected Children, Adolescents, and Young Adults: A 132-Month Follow-Up Study
    Vania Giacomet
    Pilar Nannini
    Alessandra Vigano
    Paola Erba
    Annarita Benincaso
    Giorgio Bedogni
    Dario Cattaneo
    Felicia Stefania Falvella
    Gian Vincenzo Zuccotti
    Clinical Drug Investigation, 2015, 35 : 419 - 426
  • [46] Cognitive impairment among HIV-infected adults on antiretroviral therapy in Indonesia
    Iswahyudhi
    Katu, Sudirman
    Syamsuddin, Saidah
    Bakri, Syakib
    Bachtiar, Rini Rachmawarni
    Halim, Risna
    Kasim, Hasyim
    Seweng, Arifin
    HIV & AIDS REVIEW, 2023, 22 (01): : 38 - 42
  • [47] Long-term virologic and serologic response of chronic hepatitis B virus infection to tenofovir disoproxil fumarate-containing regimens in HIV-positive patients
    Huang, Yu-Shan
    Su, Yi-Ching
    Liu, Wen-Chun
    Chang, Sui-Yuan
    Sheng, Wang-Huei
    Sun, Hsin-Yun
    Hsieh, Szu-Min
    Chuang, Yu-Chung
    Hung, Chien-Ching
    Chang, Shan-Chwen
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [48] Lipid profile and renal safety of tenofovir disoproxil fumarate-based anti-retroviral therapy in HIV-infected Chinese patients
    Yang, Junyang
    Chen, Jun
    Ji, Yongjia
    Tang, Qi
    Zhang, Renfang
    Liu, Li
    Shen, Yinzhong
    Xun, Jingna
    Song, Wei
    Tang, Yang
    Wang, Zhenyan
    Qi, Tangkai
    Lu, Hongzhou
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2019, 83 : 64 - 71
  • [49] Long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-infected, virologically suppressed adults
    Raffi, Francois
    Orkin, Chloe
    Clarke, Amanda
    Slama, Laurence
    Gallant, Joel
    Daar, Eric
    Yan, Mingjin
    Abram, Michael E.
    Friborg, Sandra
    Cheng, Andrew
    Rhee, Martin
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [50] Tenofovir disoproxil fumarate-associated hypophosphatemia as determined by fractional excretion of filtered phosphate in HIV-infected patients
    Cheng, Chien-Yu
    Chang, Shu-Yin
    Lin, Mei-Hui
    Ku, Shin-Yen
    Sun, Na-Lee
    Cheng, Shu-Hsing
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2016, 22 (11) : 744 - 747